Pharmaceutical compound
| Combination of | |
|---|---|
| Lamivudine | Reverse-transcriptase inhibitor |
| Raltegravir | Integrase inhibitor |
| Clinical data | |
| Trade names | Dutrebis |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS. It contains lamivudine and raltegravir. It is taken by mouth. Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes. It was approved for medical use in the United States in 2015.
Lamivudine/raltegravir is not available in the United States.
References
- ^ "Dutrebis (lamivudine and raltegravir)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 10 December 2017.
- "Dutrebis (lamivudine and raltegravir) tablet". U.S. Food and Drug Administration (FDA). 11 April 2016. Retrieved 24 January 2020.
- "Dutrebis (lamivudine and raltegravir) FDA Approval History". Drugs.com. 6 February 2015. Retrieved 24 January 2020.
External links
- "Lamivudine mixture with raltegravir". Drug Information Portal. U.S. National Library of Medicine.
 | This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |